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ABSTRACT
FUNCTIONAL CONSEQUENCE OF PSAT1 ASSOCIATION ON PKM2’S
INHERENT ENZYMATIC ACTIVITY
Alexis Avidan Vega
October 29, 2018
Pyruvate kinase M2 (PKM2) is predominantly found in tumors, where it allows the
cancer cell to adapt to metabolic conditions through allosteric regulation of its
activity. We recently discovered that phosphoserine aminotransferase 1 (PSAT1)
associates with and activates PKM2. Here, I sought to affirm PSAT1's ability to
increase PKM2 activity through kinetic and association studies of wild-type or
mutant PKM2 enzymes. I demonstrate that His-tagged WT and mutant PKM2
enzymes are active, exhibit different kinetics, yet cannot be activated by PSAT1.
Comparison studies using untagged WT PKM2 suggest that inclusion of the Histag disrupts PSAT1 association. In support, pull-down strategies failed to
demonstrate any PSAT1 interaction with the PKM2 proteins. Future studies should
focus on producing the PKM2 variants, potentially in untagged form, to assess their
interaction with and activation by PSAT1.

These results would add to our

understanding of these two crucial proteins that are believed to promote tumor
progression.
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CHAPTER ONE: INTRODUCTION
Glycolysis and Intermediary Metabolism

Adenosine Triphosphate (ATP) is the energy currency that is used by cells
to perform many functions, such as macromolecular synthesis and size
homeostasis. In order to generate this energy, most mammalian cells metabolize
sugars, notably glucose. Glucose is a six-carbon sugar that is transported into the
cell through various glucose transporters, termed GLUTs. Once inside the cell,
glucose carbons can be metabolized through various pathways within intermediary
metabolism that gives rise to cellular components, including ATP, that is necessary
for normal cell function (Figure 1). Initially, glucose enters glycolysis, which was
first described by Gustav Embden, Otto Meyerhof, and Jakub Parnas, that results
in the formation of pyruvic acid. Glycolysis can be divided into two sections: that
requiring energy input and that resulting in energy production.
The initial reactions within glycolysis requires energy input in order to
catabolize glucose. Hexokinase (HK) transfers a phosphate group from ATP to
glucose to generate glucose-6-phosphate (G6P).

This non-reversible step

prohibits glucose from exiting the cell. Next, phosphoglucose isomerase (PGI)
isomerizes G6P into fructose-6-phosphate (F6P), which subsequently is
phosphorylated

in

a

non-reversible

manner

by

ATP-demanding

phosphofructokinase-1 (PFK1). Like HK, PFK1 transfers a phosphate
1

Figure 1. Schematic of glucose carbon fates through
intermediary metabolism. Glucose can be fully oxidized within
glycolysis and the TCA. Glucose can also be metabolized in other
pathways, such as the pentose phosphate pathway (PPP) and serine
biosynthesis, to produce nucleic and amino acids for DNA/RNA and
proteins, respectively. Lipids are generated through fatty acid
synthesis from citrate-derived acetyl-CoA. Flux through these
pathways is primarily controlled through activity of specific enzymes,
including pyruvate kinase (PKM) and phosphoglycerate
dehydrogenase (PHGDH).
Schematic cited from https://clinicalgate.com/the-metabolism-of-cellgrowth-and-proliferation/#f0030
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group from ATP to F6P to generate fructose 1,6-bisphosphate (FBP). Aldolase
then cleaves FBP, resulting in production of dihydroxyacetone phosphate and
glyceraldehyde 3-phosphate (G3P).

Dihydroxyacetone phosphate and G3P

isomerize between one another through the activity of triose phosphate isomerase.
This energy-requiring segment of glycolysis utilizes 2 molecules of ATP for every
1 molecule of glucose catabolized.
Subsequent to G3P are the energy producing reactions of glycolysis.
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) works to oxidize G3P into
1,3-bisphosphoglycerate while also reducing nicotinamide adenine dinucleotide
(NAD+) into NADH. Phosphoglycerate kinase functions to transfer a phosphate
group from 1,3-bisphosphoglycerate to adenosine diphosphate (ADP) to produce
ATP and 3-phosphoglycerate.

This is followed by conversion of 3-

phosphoglyerate into 2-phosphoglycerate by phosphoglycerate mutase. Enolase
then acts to remove a water molecule from 2-phosphoglycerate to generate
phosphoenolpyruvate (PEP). High energy PEP is then metabolized by pyruvate
kinase (PK) to produce pyruvate, during which the high-energy phosphate group
is transferred to ADP to form ATP. Similar to HK and PFK1, PK is a non-reversible
reaction and qualifies as the last step in the glycolytic pathway. Within glycolysis,
metabolism of one molecule of glucose generates a net gain of 2 ATP and 2 NADH.
Under normal aerobic conditions, pyruvate is converted into acetyl-CoA by
pyruvate dehydrogenase that generates 1 NADH. Acetyl-CoA can then enter the
tricarboxylic acid cycle (TCA) within the mitochondrial matrix. Although the TCA
contributes only one GTP molecule per turn, 3 molecules of NADH and 1 molecule
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of reduced flavin adenine dinucleotide (FADH2) are produced. NADH and FADH2
generated from glucose-derived pyruvate oxidation act as electron donors to
acceptor complexes, such as cytochrome c oxidase, throughout the electron
transport chain located within the inner mitochondrial membrane.

As these

electrons traverse through the chain, ending in oxygen as a final acceptor, a proton
gradient is formed across the mitochondrial inner membrane. This electrochemical
gradient is then coupled to ATP synthesis by the flowing of protons through ATP
synthase.

Under physiological conditions, each NADH yields 2.5 ATP, while

oxidation of each FADH2 results in 1.5 ATP. Therefore, pyruvate oxidation
generates 23 ATP from oxidative phosphorylation and 2 ATP from substrate level
phosphorylation within the Kreb cycle. Coupled to the 2 ATP and NADH formed in
glycolysis, each molecule of glucose can yield 32 ATP under normoxic conditions.
In the case where sufficient oxygen is not available for cells to fully oxidize glucose
(hypoxia), pyruvate can be fermented into lactic acid by lactate dehydrogenase
(LDH). Although fermentation does not contribute substrate level derived ATP, it
is necessary to oxidize NADH back into NAD+ to allow glycolysis to continue [1].
In addition to hypoxia, other cellular alterations or pathologies also lead to
enhanced glycolytic flux that promote either enhanced cell proliferation or survival.
Glycolytic Shift in Tumor Cells

Flurodeoxyglucose positron emission tomography (FDG-PET) coupled with
computed tomography (CT) is a tool used to screen for metabolically active cells
in patients [2]. FDG is an analog of glucose wherein the hydroxyl located on
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carbon 2 is substituted for a radiolabeled fluorine (18F). Similar to glucose, FDG is
taken in by the cells through glucose transporters and phosphorylated by HK that
prevents it from escaping the cell. However, the fluorine inhibits the cell from
metabolizing phosphorylated FDG past this step [3-5]. PET imaging is then able
to detect the radioisotopic fluorine accumulating in tissues [2, 6]. As one of the
hallmarks of cancer is increased glucose metabolism, this procedure allows for
diagnostic imaging in cancer patients [7, 8]. In addition, FDG-PET/CT can be used
not only to initially detect tumor lesions but also monitor tumor response during
treatment [9], which is why it has become the major clinical imaging tool in
oncology.
It is well established that tumor cells take up glucose at a higher rate than
non-tumor cells. This change in glucose metabolism was first observed by Otto
Warburg in the 1920s. In his studies, less glucose was measured in outgoing
blood vessels of tumor tissues compared with that of normal tissues [7]. The
increase of glucose uptake also resulted in an increase of lactate production
(fermentation), even in the presence of oxygen. This ability for cancer cells to
selectively metabolize glucose to lactate under normoxic conditions is termed
aerobic glycolysis, or the “Warburg Effect” (Figure 2). Warburg concluded that this
deviation from normal glucose metabolism was brought upon by functionally
impaired mitochondria in tumor cells [7, 10].
Converse to Warburg’s idea that mitochondrial dysfunction was the primary
causal shift towards aerobic glycolysis in tumor cells, it has now been established
that the vast majority of cancers maintain active mitochondria. [11, 12]. For

5

Figure 2. Representation of metabolic changes upon
transformation from normal to cancer cell. Glucose is
preferentially metabolized within the TCA for oxidative
phosphorylation. However, cancer cells change their metabolism to
increase production of macromolecules that are necessary for
increased proliferation/growth. In addition, tumors secrete increased
levels of lactate, even in the presence of oxygen, which helps
promote invasion and metastasis.
Schematic cited from Jó´zwiak P, Forma E, Bryma,M, andKrzek and
A (2014) O-GlcNAcylation and metabolic reprograming in cancer.
Front.Endocrinol. 5:145.
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example, knockdown of LDH-A increased mitochondrial respiration, leading to the
conclusion that LDH-A was competing with the mitochondria for glucose-derived
pyruvate [11]. If the majority of tumor cells have functional mitochondria, other
cellular forces must be promoting this metabolic shift towards aerobic glycolysis.
One possible explanation for the Warburg effect could be the result of abnormal
activation of certain genes, termed oncogenes, or inactivation of others, e.g. tumor
suppressors [9, 11, 13]. Substantial work has now demonstrated the contribution
of certain transcription factors or signaling pathways which control the Warburg
Effect, including hypoxia inducing factor 1 (HIF1), MYC, and the AKT pathway
[14, 15]. These pathways have been observed to alter the activity of certain
glycolytic enzymes to increase glucose metabolism [14, 16, 17]. Among the
enzymes that are direct targets of these upstream factors that increase glycolytic
rate include GLUT1, HK, PFK, PK, and LDH [12, 18-24].
Despite defining mechanisms as to how tumors increase glycolysis, the
question remains as to why tumor cells would use such an inefficient technique to
generate ATP. It is now believed that tumor cells enhance their glycolytic rate, not
for increased energy production, but because glycolytic intermediates are used to
generate key components of proliferation [25]. For example, after glucose is
converted into G6P in glycolysis, it can then be shunted into the Pentose
Phosphate Pathways (PPP) (Figure 2). Here, G6P continues to be metabolized to
ultimately

generate

ribonucleotides

and

reduced

nicotinamide

adenine

dinucleotide phosphate (NADPH) [26-28]; both being necessary for cell
proliferation [29]. The ribonucleotides produced by PPP are utilized to synthesize
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nucleic acids, while the NADPH is consumed when producing fatty acids,
cholesterol, and hormones.

NADPH is also required to re-establish reduced

glutathione (GSH), which protects cells from reactive oxygen species (ROS) [30].
Glycolytic intermediates may also feed into the serine synthetic pathway.
Specifically, 3-PG is used as a substrate to produce 3-phosphohydroxypyruvate
(PHP) through the activity of phosphoglycerate dehydrogenase (PHGDH).
Phosphoserine aminotransferase 1 (PSAT1), with the co-factor pyridoxal 5’phosphate (PLP), transfers an amino group from L-glutamic acid to PHP. This
results in the production of phosphoserine (P-ser) and -ketoglutarate (KG).
Phosphoserine phosphatase (PSPH) can then catalyze the reaction that removes
an inorganic phosphate from P-Ser to produce serine. While serine can be actively
generated through this pathway, this non-essential amino acid can also be readily
taken in from the extracellular environment [31].
As an amino acid, one of the functions of serine is as a component of newly
synthesized proteins. In addition to this, serine can also be used to produce
glycine through the transfer of one carbon to tetrahydrofolate (THF) to produce
5,10-methylene-THF [31-34]. 5,10-methylene-THF is required for the production
of both purines and methionine [34]. Methionine can either continue on to be
utilized as an amino acid for protein synthesis, or be used to produce S-adenosyl
methionine (SAM) [31]. SAM is a substrate for methylation of DNA or RNA, as well
as a precursor for production of homocysteine [35]. Homocysteine can then be
used to produce GSH with the assistance of serine [31]. Given all of these cellular
benefits to rapidly proliferate and protection against apoptosis, it is not surprising
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that tumor cells upregulate enzymes found in the serine synthesis pathway [36,
37].
Mediators of Altered Glycolysis and Tumorigenesis

With the increased availability of glycolytic intermediates, tumor cells can
generate more biomolecular components for proliferation and cell survival. This is
accomplished by altering the rate of glycolysis through certain glycolytic
isoenzymes. GLUT1 is shown to be upregulated, which in turn increases the rate
of glucose uptake [18]. Increased expression of HK2 in tumor cells can arise from
both increased gene copy number or through direct transcriptional activation by
oncogenes, such as c-Myc [24, 38]. Apart from increasing copy number or protein
levels, increased glycolysis can occur through the utilization of small molecules
capable of stimulating glycolytic enzymes. Fructose 2,6-bisphosphate (F26BP) is
one such small molecule known to stimulate PFK1. By increasing PFK1’s affinity
for F6P, F26BP allows for higher levels of glucose utilization [19, 39-41]. Tumor
cells also exhibit elevated expression of LDH [42], with the LDH-A isozyme being
associated with metastasis and cell proliferation [11, 43, 44]. PK has also been
shown to not only alter the rate of glycolysis, but also have other functions, which
help facilitate the formation of tumors.
PK is known to have tissue-specific isoforms. While PKL is expressed in
liver tissues and PKR in erythrocytes, variants of PKM are found in all other tissues
[45, 46]. Variants from the PKM gene can be divided into two groups: The M1 form
found in the brain and skeletal muscles, and the M2 form found in remaining
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tissues as well as in undifferentiated cells, such as embryonic cells [47]. As the
PKM gene is responsible for encoding both isoforms, alternative splicing dictates
which isoform is translated.
Of the exons within the PKM gene, it is the inclusion of either exon 9 or 10,
and the exclusion of the other, that dictates the isoform produced (Figure 3). Both
exon 9 and 10 of the PKM gene encode for 56 amino acids. Of these, 34 are
identical between exons while the remaining 22 are exclusive to their respective
isoform [48, 49]. Under normoxic conditions, exon 10 is spliced out of the primary
mRNA to produce PKM1.

The protein that is translated from this mRNA is

observed as a fully active tetrameric protein. However, under hypoxic conditions
that are frequently seen within tumor cells, exon 9 is spliced out in preference for
incorporation of exon 10 [48]. In addition to hypoxia, other cellular factors can
promote this differential splicing. In particular, oncogenic c-Myc drives expression
of heterogenous ribonucleoproteins (hnRNPs). HnRNPs are splicing factors that
lead to alternative splicing for inclusion of exon 10 and expression of PKM2.
Alternatively, inclusion of exon 10 can also be facilitated by other factors, including
serine-argenine splice factor 3 (SRSF 3) [50-52]. These splicing mechanisms
result in production of PKM2 that, in contrast to PKM1, is present as multiple
oligomeric states: monomeric, dimeric, or tetrameric [46]. While discussed in more
detail below, it has been demonstrated that PKM1 and PKM2 exhibit different
levels of PK activity, with PKM2 being the least active. This finding has led to the
postulation that tumor cells utilize the less active PKM2, due to its dimeric state, to
reduce the rate of glycolysis and allow for glycolytic intermediates to accumulate
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Figure 3. Representation of PKM alternative splicing
mechanisms that produces either PKM1 or PKM2. Both exon
9 and exon 10 encode for 56 amino acids; of which, 34 are identical
and 22 are exclusive to their respective isoforms. Inclusion of exon 9
and exclusion of exon 10 results in expression of PKM1. However,
oncogenic factors, such as c-Myc promote hnRNPs expression that
suppresses splicing at exon 9 and results in incorporation of exon 10
and exclusion of exon 9 from the final protein coding mRNA.
Schematic cited from Nicholas Wong, Jason De Melo, and Damu
Tang, ng, Tang, ng, De Melo, and Damu Tang, PKM2, a Central
Point of Regulation in Cancer Metabolism . International Journal of
Cell Biology, vol. 2013, Article ID 242513, 11 pages, 2013
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above the PK step (Figure 4) [38]. These glycolytic intermediates can then be
shunted to different pathways, which assists in cell proliferation and survival,
including nucleotide biosynthesis stemming from pentose phosphate activity and
one carbon metabolism driven by increased flux through the serine synthetic
pathway. Beyond expression, allosteric regulation of PKM2 allows for “metabolic
tuning” in such a way to either increase or decrease its activity (tetrameric versus
dimeric), depending on the needs of the tumor cell (Figure 4) [53].
In the absence of any allosteric modulator, purified human PKM2 has been
recorded to have a maximum velocity (Vmax) of 166.3mol/min and a Km for PEP
of 0.86mM [46].

In contrast, PKM1, which primarily exists in a highly-active

tetramer state, exhibits a Vmax of 345.6 mol/min and Km of 0.05mM for PEP. One
molecule that has previously been demonstrated to selectively increase PKM2
activity is the glycolytic intermediate, FBP [54, 55]. Biologically, this allows for a
forward feedback loop, wherein if glycolytic intermediates are in sufficient quantity,
activation of PKM2 would result in further glycolytic flux and metabolism of glucose
carbon into downstream processes. The addition of FBP has been documented
to promote the formation of tetrameric PKM2 from the available monomer/dimers
[55]. This results in a modest increase in PKM2 activity (213 mol/min) and a
significant decrease in Km for PEP to 0.10mM [46]. Unlike PKM2, PKM1 activity
does not increase in the presence of FBP. This is due to PKM1 being present
exclusively as a tetramer. Recently, it has been found that serine can also increase
the activity of PKM2 [56-58]. Similar to FBP, serine induces strong tetramer
formation to enhance PKM2 activity and also functionally works as a feedback
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Figure 4. Comparison between high active tetramer and
low active dimer of PKM2. In the tetrameric form, PKM2
catalyzes the reaction to produce pyruvate at a high rate for energy
production. In the dimeric form, the reaction rate of PKM2 is lowered
that leads to accumulation of glycolytic intermediates which can be
shunted to increase biomass and produce biomolecules useful in
proliferation.
Schematic cited from Witney, T.H., et al., PET imaging of tumor
glycolysis downstream of hexokinase through noninvasive
measurement of pyruvate kinase M2. Sci Transl Med, 2015. 7(310):
p. 310ra169.
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mechanism. As explained earlier, serine is derived from the glycolytic intermediate
3-PG, which, if in excess, is shunted into the serine biosynthetic pathway. As
serine levels become abundant in the cell, serine can activate PKM2 and lead to
increased glycolysis and reduction in 3-PG levels. Although the binding pocket for
serine can be found across different isoforms of PK, serine is unable to increase
the activity of the M1 or L/R isoforms [56]. Contrary to FBP and serine, Christofk
et al. demonstrated that phosphotyrosine peptides, of the tyrosine kinase signaling
pathway, reduced the activity of PKM2 [59]. By acting as a competitor for FBP’s
binding site, phosphotyrosine peptides can cause the dissociation of PKM2 and
FBP. The dissociation then results in PKM2 shifting back to a less active state.
By doing so, the cell builds up the glycolytic intermediates to be shunted to multiple
different pathways that can be used to facilitate proliferation.
A substantial amount of work has been done on defining the metabolic
characteristics of PKM2, particularly as it relates to its pro-tumorigenic effects. Yet,
more recently, studies have demonstrated that PKM2 exhibits non-metabolic
functions that also may contribute to tumorigenesis. Outside of glycolysis, PKM2
can act as a specific protein kinase or interact with other proteins. Although
normally located in the cytoplasm where it functions in glycolysis, PKM2 has also
been seen to translocate into the nucleus [60]. While functioning as a protein
kinase, PKM2 can phosphorylate Histone H3 on tyrosine 11 (H3T11) [60, 61] that
leads to changes in gene expression, including Bub-3 for cell-cycle control [62],
and B-cell lymphoma 2 (BCL-2) to prevent apoptosis [63]. In addition, nuclear
PKM2 directly associates with β-catenin and assists in transactivating downstream
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target genes, such as c-Myc and CCND1 (encodes for cyclin D1) [60, 61]. Within
the nucleus, PKM2 can also interact with several other proteins such as HIF-1,
octamer-binding transcription factor 4 (Oct-4), and suppressor of cytokine
signaling 3 (SOCS3) to act as a coactivator for gene expression [60, 64-66]. Taken
together, prior studies have emphasized the relevance of PKM2 in contributing to
tumorigenic growth, not only from its altered activity within glycolysis, but as an
important mediator in promoting gene expression through its non-canonical protein
kinase and protein:protein interactions. Therefore, identifying additional binding
partners may provide further insight into the unique function of PKM2 in cancer.

PSAT1 as a Novel PKM2 activator

Activity within multiple biochemical pathways are changed in response to
tumor initiation and progression. Among these, enhanced flux within serine
metabolism has been demonstrated in tumors from various tissue types. Previous
studies have attempted to understand the pro-tumor advantage for increased
serine production in various cancers, such as breast and lung [67, 68]. Serine
metabolism provides amino acids for protein synthesis and promotes one carbon
metabolism through formation of methyl-tetrahydrofolate (mTHF) from the
conversion of serine to glycine. mTHF is a precursor required for novel nucleotide
production, which is necessary for rapidly proliferating cells. In addition, the
aminotransferase reaction of PSAT1 promotes glutamine metabolism as a source
of anaplerotic carbon for the TCA cycle through the conversion of glutamate to
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αKG [67]. This elevated serine biosynthetic activity observed in tumors is
accomplished through increased expression of enzymes within this pathway,
including PSAT1 (Figure 5).
Prior attempts to understand the relevance of serine synthetic enzymes,
including PHGDH and PSAT1, in tumor progression has been done using knockdown strategies in tumor cells. Within breast cancer cells, reduction of either
PSAT1 or PHGDH reduced cell proliferation, which could be partially rescued by
addition of downstream metabolites, such as αKG, non-essential amino acids, and
nucleosides to the culture medium [69]. Yet, this result is somewhat surprising in
that serine can be actively taken up from the outside environment and presumed
to be utilized in an identical manner as synthesized serine. While some progress
has been made in identifying requirements for serine synthesis in promoting tumor
progression, the relevance for this pathway is not completely understood. Multiple
metabolic enzymes, such as enolase and PKM2, have been identified to have
alternative functions, including protein-protein interactions. We postulated that
enzymes within the serine biosynthetic pathway, specifically PSAT1, may have
unknown binding partners. In addition to its role in serine production, these
interactions may also promote pro-tumor activities.
To identify potential protein: protein associations with PSAT1, the Clem lab
performed a pull-down experiment incorporating protein lysates from A549 lung
cancer cells and GST-tagged PSAT1 bound to a glutathione bead column. Mass
spectrometry analysis of specific associating proteins identified PKM as a new
interacting protein of PSAT1. As the peptide fragments did not distinguish between
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PKM1 or PKM2 (coverage only in identical amino acid regions of both proteins),
co-immunoprecipitation (Co-IP) analysis was done using purified commercially
available (Sigma) untagged purified PKM1 (PKM1-Sigma) and PKM2 (PKM2Sigma) with untagged PSAT1 that was produced and purified within the Clem lab.
To understand a potential biological effect of this interaction, in-vitro
enzymatic assays were done to determine if this interaction had any effect on
pyruvate kinase enzyme activity. Activity of PKM1-Sigma and PKM2-Sigma were
done in the absence or presence of PSAT1 using an end-point activity assay
(Kinase ADP Glo). As PK generates ATP from ADP, ATP generates light, through
luciferase-mediated conversion of luciferin to oxyluciferin, which is presented as
relative light units. Using this approach, addition of PSAT1 resulted in a dosedependent increase in PKM2-Sigma activity up to four-fold activation in the
presence of 400nM PSAT1. PSAT1 failed to increase PKM1-Sigma activity at any
concentration. To address whether the native PSAT1:PKM2 interaction is
promoting the increase in activity, an aliquot of PSAT1 was boiled to denature the
protein before addition to the enzyme assay. Loss of native formation of PSAT1
failed to activate PKM2-Sigma, suggesting that it is the protein-protein interaction
selectively with PKM2 that is promoting pyruvate kinase activity.
To initially understand which domains or amino acids within PKM2 may be
responsible for interacting with PSAT1, a computational comparison was done
between the crystal structures for both PKM2 and PKM1. The 22 amino acid
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changes between incorporation of exon 9 (PKM1) or exon 10 (PKM2) are localized
within a loop structure on the external region of the PKM protein (Figure 6A,
illustrated in cyan on left side of crystal structure). This suggested that this site may
be the region responsible for the PKM2:PSAT1 interaction. To test the amino acids
within this region that may contribute to PSAT1 interaction, we randomly mutated
separate amino acids within the non-synonymous region to those amino acids
found in PKM1 (Figure 6B). Four distinct site-specific mutants were constructed:
Mutant 1 (MT1) containing L391R and Q392K, Mutant 2 (MT2) containing P402S
and I403H, Mutant 3 (MT3) containing P402S, I403H, and R398V, and Mutant 4
(MT4) containing R398V. To avoid the potential for dramatic changes in the PKM2
structure upon mutation, the amino acid modifications were constructed in order to
revert those amino acids to those found in PKM1. FLAG-tagged constructs
encoding WT or the mutant PKM2 proteins were expressed in HEK293T cells and
immunoprecipitated using anti-FLAG antibody conjugated sepharose beads.
Immunoblot analysis of immunoprecipitated complexes found that while PKM2
Wild-Type (WT), MT1, MT2 and MT4 interacted with PSAT1, amino acid changes
in MT3 resulted in loss of PSAT1 association.
We hypothesize that PKM2 mutations will abolish activation by PSAT1
through disruption of the PSAT1:PKM2 interaction. However, these data do not
exclude the possibility that the point mutations change the overall structure of PK
and contribute to the loss of binding. Furthermore, it is plausible that the mutations,
alone, could alter the activity of PK in such a way to differ from the wild-type
enzyme. For this, we will determine recombinant WT and MT(1-4) PKM2 activity
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Figure 5. Schematic of serine metabolism. Serine is be
synthesized from the glycolytic intermediate 3Phosphoglycerate. Synthesis of serine leads to the production
of alpha Ketogluterate, which can go on to enter the carboxylic
acid cycle. Serine can also be metabolized by cells to
synthesize nucleotides. Schematic edited from: Cancer's sweet
tooth for serine. Breast Cancer Res. 2011;13(6):317.
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Figure 6. Superimposed crystal structures of PKM2 and
PKM1 identify region of divergent sequence. A) Crystal
structure of PKM2 (cyan) overlaid atop the crystal structure of
PKM1 (blue). PKM2 contained an outer looped region (“) that
was not shared with PKM1. B) Mutations on PKM2, reverting
the amino acid on PKM2 WT to those seen in PKM1. Mutation
sites colored in red and highlighted in gray
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in the presence or absence of PSAT1 (Aim1) and assess the direct interaction with
recombinant WT and MT(1-4) PKM2 with PSAT1 (Aim2). Completion of these
studies aims to define the kinetic parameters of WT and MT(1-4) PKM2, PSAT1’s
effect on their activity, and confirm that PSAT1’s effects on activity is due to direct
association.
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CHAPTER TWO: MATERIALS AND METHODS
Vector Generation
Plasmids containing cDNA encoding WT or mutant PKM2 was generously
provided by Rumeysa Biyik-Sit for construction of these expression vectors.
cDNAs for PKM2-WT, -MT1, -MT2, -MT3, or -MT4 were sub-cloned from the
provided pcDNA3.1 vector into either the pGEX-4T-1 (GST-fusion) or pET30a (Hisfusion) expression plasmids. Briefly, 1g of plasmid was incubated at 37oC for 15
minutes in a solution containing 2L of Fast Digest Buffer, 1L of BamHI, 1L of
EcoRI, and brought up to 20L with Nuclease-Free water. Subsequently, the
digestion reactions were loaded onto a 1% agarose gel and ran for 30 minutes at
100V. Bands corresponding to cut destination plasmids (pGEX-4T-1 or pET30a)
or PKM2 cDNA were excised from the gel and centrifuged through a Gen Elute
Agarose Spin Column (Sigma Cat#56500) at 18,000 x g for 10 minutes. The elute
was then ethanol precipitated by addition of 1% of 3M sodium acetate at pH 5.2
and 2.5 x volume of absolute ethanol and incubated for 20 minutes at -80oC. The
solution was centrifuged for 20 minutes at 4oC and 12,000 rpm. The supernatant
was removed, and the pellet was washed with 500L of 70% ethanol. Centrifuge
was repeated to remove the supernatant and any excess ethanol. The pellet was
resuspended in 10L of Nuclease-Free water. The concentration of DNA was
taken by nanodrop. Molar ratio of 1:1.73 insert to vector DNA was incubated
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overnight at 4oC in a solution containing 1L of ligase buffer, 1 unit of T4 DNA
Ligase, and brought up to 10L with water.
Transformation of bacterial cells
1L of ligation mixture was added to one vial of TOP10 DH5α competent cells and
incubated on ice for 30 minutes. Cells were then heat-shocked for 30 seconds at
42oC and immediately transferred to ice and incubated for an addition 2 minutes.
250L of S.O.C medium was added to the bacterial solution and incubated at 37oC
for 1 hour. Bacterial cells were spread onto LB plate containing appropriate
antibiotics and incubated overnight at 37oC. Cells transformed with pGEX4T-1
were spread onto a plate containing ampicillin; cells transformed with pET30a were
spread onto a plate containing kanamycin.
Construct Verification
A single bacterial colony was harvested from the transformed LB agar plate
and grown in 5mL of LB containing appropriate antibiotic overnight at 37 oC.
Bacterial cells were pelleted by centrifugation for 3 minutes at 8,000 rpm, and
plasmid DNA was purified using plasmid miniprep kit following the manufacturer’s
protocol (Qiagen Cat#27106) [ref: QIAprep® Miniprep Handbook 2nd Edition. May
2012.

Available:

https://www.qiagen.com/us/resources/resourcedetail?id=89bfa021-7310-4c0f90e0-6a9c84f66cee&lang=en.].
Plasmid DNA was then sequenced to verify incorporation of WT or MT
PKM2. For pGEX4T-1 vectors, 250ng of plasmid DNA was combined with either
2L

of

Forward

Sequencing
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Primer

(5’-

GATCGAATTCATGTCGAAGCCCCATAGTGAAG-3’)

or

2L

of

Reverse

Sequencing Primer (5’-CTGGGGATCCTCACGGCACAGGAACAACACGC-3’).
Samples were then sent to Eurofins Genomics to be sequenced. For pET30a
vectors, 250ng of plasmid DNA was sent to Eurofins Genomics to be sequenced
using company provided T7 and T7 Terminator primers. Sequences were then
assessed through a BLAST search to verify presence of the respective PKM2
cDNAs and to ensure that each was incorporated into the plasmid in the correct
orientation and in-frame.
Expression of Recombinant GST-PKM2 Proteins
A single colony of transformed bacteria was grown in a sterile Erlenmeyer
flask, containing 100mL of LB and 100ug/mL of Ampicillin, and incubated overnight
at 37oC. 100mL of fresh LB and ampicillin was added to the starter culture and
incubated at 37oC for an additional 3 hours. When the bacterial culture reached
an OD600 of ~ 0.7, IPTG was added to final concentration of 1mM and incubated at
37oC for additional 4 hours.

Bacterial cells were then pelleted and stored,

overnight, in -80oC. The pellet was thawed and resuspended with 4mL of B-PER
lysis buffer (Pierce, containing 2L of lysozyme, 2L of DNase I, and 10L of
Protease Inhibitors for every 1 mL of B-PER buffer) for every gram of bacterial
pellet. The resuspended pellet was incubated for 15 minutes at room temperature
followed by centrifugation for 5 minutes at 15,000 x g in 4 oC to obtain bacterial
lysate.
GST-PKM2 Protein Purified by Affinity Chromatography
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Glutathione sepharose containing spin-columns were washed twice with 1X
PBS and centrifuged at 700 x g for 2 minutes at 4oC. Bacterial lysates were added
to columns and incubated for 60 minutes at 4oC on a rocking platform, followed by
centrifugation at 700 x g. The flow-through was collected and saved for further
analysis. Columns were washed 3 additional times with PBS, with an aliquot of
each wash being saved for future analysis. 1mL of Glutathione Elution buffer
(50mM Tris HCl, 10mM reduced glutathione, and adjusted to pH 8.0) was added
to each column and incubated overnight at room temperature. Columns were
centrifuged to collect eluted protein and repeated 2x using fresh elution buffer. The
reduced glutathione was removed from the elution fraction through dialysis with
1000X volume of buffer containing: 25mM of Tris HCl at pH 7.4, 100mM of KCl,
5mM of MgCl2, and 10% glycerol for 2 hours at 4oC. The buffer was changed, and
dialysis was continued for an additional 16 hours at 4oC.
Expression and purification of His-tagged PKM2 Proteins
Expression and purification of His-tagged PKM2 variants was performed
following the same procedure as that for GST-tagged PKM2 with minor
modifications. Briefly, the frozen pellet was thawed at room temperature for 15
minutes followed by incubation in 5mL of Binding Buffer (50mM Tris HCl pH 8.0,
10mM MgCl2, 300mM NaCl, 5mM Imidazole, 10% Glycerol) containing 10L
lysosome and 10L of DNase for 15 additional minutes.

Lysates were then

sonicated 3X in 15 second intervals and added to pre-washed Ni-NTA beads
overnight in 4oC. Poly prep chromatography columns were washed the following
day 2X with 5mL of Washing Buffer (50mM Tris, 10mM MgCl2, 300mM NaCl,
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30mM Imidazole, 10% glycerol) prior to the addition of lysate/bead mixture. The
resin was washed 4 times with Wash Buffer followed by incubating columns at
room temperature with 1 mL of Elution Buffer (50mM Tris, 10mM MgCl2, 250mM
NaCl, 250mM Imidazole, and 10% glycerol) for 1 hour. Aliquots of starting lysate,
washes and elutions were collected and stored for future analysis. Imidazole was
removed from elutions through dialysis using 50mM Tris, 10mM MgCl2, 25mM
NaCl, and 10% glycerol overnight at 4oC. Protein concentration was determined
by Nanodrop, and subsequently aliquoted, flash-frozen in LN2, and stored in -80°C.
Coomassie Stain
Aliquots from bacterial lysates, column washes, and dialyzed elutions were
assessed for protein content and purity by Coomassie stain. Samples were loaded
onto 10% SDS-Polyacrylamide Gel Electrophoresis (PAGE) gel and ran for 30
minutes at 200V. The SDS-PAGE gel was then stained with Coomassie Brilliant
Blue R250 Stain for 30 minutes. The stained gel was then washed with a de-stain
solution containing 10% acetic acid, 20% methanol.
Immunoblotting
Protein samples were mixed 1:1 with 2X SDS-sample buffer and separated
by 10% SDS-PAGE at 200v for 30 minutes. Proteins were then transferred to
PVDF membrane in transfer buffer for one hour at 200v. Membranes were
incubated in blocking buffer (5% non-fat dry milk in TBS-Tween) for one hour.
Primary antibodies at defined dilutions were placed on membranes overnight at
4°C with constant rocking. After 3X washes with TBS-Tween, membranes were
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incubated with appropriate secondary antibodies and protein was detected using
ECL chemiluminescent reagent.
Antibodies
For Western blot analysis, membranes were probed with 1:1000 anti-HIS
(Cell Signaling; 12698S), anti-PKM2 (Cell Signaling; 4053S), or anti-PSAT
(ProteinTech; 20180-1-AP). Anti-rabbit HRP-linked secondary antibody (1:5000;
Thermo; 31460) was used to detect proteins.
Protein Cross-Linking
Disuccinimidyl suberate (DSS) cross-linking agent was reconstituted to
25mM in DMSO. 50ng of recombinant His-PKM2 WT, MT1, MT2, MT3, or MT4
was diluted in 60μL 1X PBS with subsequent addition of DSS to a final volume of
10 or 20μM. Samples were then incubated for 15 minutes at 37°C. To stop the
cross-linking reaction, Tris (pH 7.4) was added to a final concentration of 50mM
and incubated for 15 minutes at room temperature. 60L of 2X sample buffer was
added to the reaction and heated for 5 minutes at 95°C. 30L of sample was
separated by SDS-PAGE and oligomeric state of PKM2 was determined by
immunoblot analysis.
PKM2 Kinetics Assay
Enzyme kinetics of PKM2 WT and mutant proteins were determined using
an LDH enzyme coupled assay. PKM2-derived pyruvate is rapidly converted by
LDH to lactate with equimolar oxidation of NADH to NAD+. For the assay, a 10x
Reaction Buffer stock was made containing 500mM Tris HCl pH 8.0, 500mM KCl,
and 50mM MgCl2.

Assay master mixes were generated containing a final
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concentration of 1X Reaction Buffer, 0.6 mM ADP, 0.54 mM NADH, 0.016g/uL
LDH, and different concentrations of PEP ranging from 0.025 to 4mM. 100L of
assay solution was then aliquoted into a 96-well plate in triplicate for each PEP
concentration. Separately, PKM2 enzymes were incubated with or without 400nM
PSAT1 or 500M FBP in 1X reaction buffer for 30 minutes at 37°C. To initiate the
kinetic reaction, PKM2 samples were then added to the assay solution to a final
concentration of 2.5nM PKM2. NADH absorbance was recorded at 340nm every
30 seconds for 10 minutes using a Biotek spectrophotometer plate reader.
Absorbance readings were plotted against time and rates of NADH consumption
(OD/min) at each PEP concentration were determined by the slope of linear
equation. Rates were then converted to μmol/min using the NADH extinction
coefficient (6220M-1cm-1). Initial velocities were then plotted against each PEP
concentration and kinetic parameters (Vmax and KM) of each PKM2 protein with or
without PSAT1 or FBP were determined by non-linear regression analysis using
Prism software.
Pulldown Assay using His-PKM2
500ng of PSAT1 was incubated with 50ng of WT or mutant His-PKM2 in
500L of Binding Buffer for 45 minutes at 4oC. 30L of Ni-NTA sepharose bead
slurry was washed with Washing Buffer, reconstituted in 0.1% BSA and incubated
for 1 hour at 4oC. Beads were then added to the His-PKM2:PSAT1 solution and
incubated overnight at 4oC. Ni-NTA beads were centrifuged and washed twice.
30L of 1x Laemmli Sample Buffer was added to the Ni-NTA beads and heated at
95oC for 5 minutes The supernatant was then loaded onto an SDS-PAGE and
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presence of PSAT1 and PKM2 were analyzed by immunoblotting using anti-His or
anti-PSAT1 antibodies.
Co-Immunoprecipitation of His-PKM2:PSAT1
50ng of PSAT1 and 500ng WT or mutant His-PKM2 was incubated in 500L
of Lysis Buffer at room temperature for 45 minutes. 1g of anti-PSAT1 antibody
or control IgG was added to the protein mixture and incubated overnight at 4oC.
Protein G Dynabeads (Invitrogen) (50L per immunoprecipitation) were washed
twice in 250L of Ab Wash Buffer, resuspended in Antibody binding buffer
(Invitrogen) and added to protein samples for 45 minutes at room temperature with
end-over-end rocking.

Immunocomplexes were collected by placement on

Magnarack (Invitrogen) and subsequently washed 3 times with 200L of Wash
Buffer. 25L of 1x Laemmli Buffer was added to the beads and incubated at 95oC
for 3 minutes. Solution was placed back on Magnarack for 2 minutes, and protein
supernatant was separated by SDS-PAGE. Presence of PSAT1 and PKM2 were
assessed by immunoblotting using anti-PSAT1 or anti-His antibodies.
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CHAPTER THREE: RESULTS
Expression of GST-PKM2
The initial objective of these studies was to recombinantly express and
purify PKM2 WT and PKM2 variants harboring the mutations indicated in Figure 7.
Previous reports have demonstrated that utilizing a GST-fusion system could
assist in properly folding proteins that are prone to aggregation [70]. I chose to
express PKM2 as a GST-fusion protein utilizing the pGEX4T-1 vector system that
encodes a GST-tag on the N-terminus of the fusion protein. cDNAs encoding WT,
MT1, MT2, or MT3 were previously generated within the lab using site-directed
mutagenesis and sequenced to verify correct mutational status (Figure 7A-D).
Each cDNA was sub-cloned into the pGEX4T-1 vector and underwent DNA
sequencing and subsequent BLAST search to ensure correct orientation and
presence of mutations.
Purification of GST-PKM2
Plasmids that had been verified to encode WT or mutant GST-PKM2 were
transformed into BL21(DE3) cells. Following the protocol outlined by Park et al. to
increase yield of GST-fusion proteins [72], I initially attempted to purify WT GSTPKM2 using a Sarkosyl: Triton X100 buffer for bacterial extraction [73]. PKM2 has
a molecular weight of 56 kDa, and with the addition of the GST-(27kDa), the fusion
protein is expected to have a molecular weight of ~80 kDa. While I was able to
extract proteins from both un-induced and IPTG-induced bacteria, no specific
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Figure 7. Sequence analysis of cDNA encoding WT and mutant
variants of PKM2 Plasmid DNA was commercially sequenced by Eurofins
Genomics. Computational BLAST analysis revealed correct orientation and
inclusion of cDNA encoding (A) WT, (B) MT1, (C) MT2, (D) MT3, (E) MT4
PKM2.
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GST-PKM2 was collected from the glutathione beads as demonstrated by SDSPAGE and Coomassie stain (Figure 8). I then attempted an alternative strategy
for protein purification using the Tris-based B-PER solution (Bacterial Protein
Extraction Reagent, ThermoFisher). Utilizing this bacterial lysis protocol followed
by glutathione bead affinity chromatography, I was able to recover GST-PKM2 WT,
MT1, MT2, and MT3 (Figure 9).

Enzymatic Activity of GST-PKM2
To determine whether the GST-PKM2 enzymes had activity, I utilized an
enzyme-coupled assay incorporating LDH-mediated consumption of NADH
(Figure 10A).

As PKM2 generates pyruvate from PEP, LDH subsequently

metabolizes pyruvate to lactate while simultaneously converting NADH to NAD +,
in an equal mole to mole ratio. Loss of NADH absorbance in a linear fashion allows
for the indirect measurement of PKM2 activity. Using this approach, I recorded no
enzymatic activity above background with any of the GST-PKM2 enzymes (WT,
MT1, M2 or M3) at 0.5 mM PEP (Figure 10B). To ensure the functionality of the
enzyme assay, I included untagged PKM2-Sigma as a positive control. As shown
in Figure 11B, PKM2-Sigma exhibits pyruvate kinase activity based on the linear
consumption of NADH. The lack of activity of the GST-PKM2 proteins suggest that
the addition of the large GST tag at the N-terminus of PKM2 may be inhibiting the
catalytic activity of the enzyme.

Thrombin Cleavage of GST-tag from PKM2 Protein
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Figure 8. Extraction of GST-PKM2 WT from bacterial
lysates using ionic detergent (Sarkosyl). Wild-type GSTPKM2 expression in transformed BL21 cells was induced with IPTG
as described in the materials and methods. Cell pellet was then
extracted using Sarkosyl-Triton X-100 buffer and proteins purified
by glutathione elution from glutathione linked sepharose beads.
Lysates or elutions from induced and non-induced bacteria were
subjected to SDS-PAGE and Coomassie staining.
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Figure 9. Purification of GST-PKM2 enzymes using an alternative
extraction protocol. Expression of fusion GST-PKM2 proteins in
transformed BL21 cells was induced by IPTG as described in the materials and
methods. Proteins were extracted using B-PER buffer (Thermo Fischer) with
addition of DNase and lysozyme. GST-PKM2 proteins were purified by
glutathione elution from glutathione-linked sepharose beads. Lysates and
elutions (GST-PKM2) were subjected to SDS-PAGE and Coomassie stain.
Expected molecular weight of GST-PKM2 proteins is 80kDa.
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Figure 10. Kinetic analysis of GST-PKM2 recombinant enzymes. (A)
Scheme of the LDH-coupled assay used to measure PKM2 activity through
consumption of NADH, which is assessed by loss of NADH absorbance at
340nm. (B) Representative kinetic assay comparing WT, MT1, MT2, and MT3
GST-PKM2 at 4nM protein concentration and 0,5mM PEP. Data is
demonstrated as loss of absorbance of NADH at 340nm over time. Addition of
water was used as negative control and positive control represents addition of
untagged PKM2-Sigma.
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To determine whether the GST-tag was responsible for the inactivity of
PKM2, I attempted to purify PKM2 from induced GST-PKM2 bacteria lysates
through removal of GST-tag by thrombin cleavage.

The pGEX-4T-1 vector

encodes a thrombin cleavage site between the GST-tag and the N-terminal amino
acid of PKM2. After the final wash during glutathione-sepharose purification, I
incubated protein-bound beads for 45 minutes at room temperature with Thrombin
protease to release cleaved PKM2 from the bead matrix. SDS-PAGE and
Coomassie stain analysis of cleaved elutions revealed no recovery of PKM2
protein (Figure 11). Together, these data indicate that while my experimental
conditions are sufficient to express WT and MT GST-PKM2 proteins, they are
inactive and thrombin cleavage under these conditions is ineffective in recovering
PKM2 enzymes.
PKM2 was sub-cloned into a pET vector encoding a smaller fusion tag
To circumvent the potential issue of the large GST tag affecting PKM2
activity, I decided to use a different protein fusion expression system. The PKM2
cDNAs were sub-cloned into the pET30a vector, which encodes for a small 6x Histag at the N-terminal end of the fusion protein (1kDa compared to 27kDa GSTtag). Initially, I utilized the extraction protocol for the GST-fusion proteins discussed
above (ie buffer conditions) in conjunction with affinity purification with imidazole
elutions from Ni-NTA beads. SDS-PAGE analysis demonstrated large amounts of
non-specific proteins within the imidazole elution fractions (Figure 12A) and was
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Figure 11. Thrombin cleavage of recombinant GST-PKM2 proteins.
Bacterial lysates induced for GST-PKM2 WT, MT1, MT2, and MT3 were
incubated with glutathione sepharose. Immobilized GST-PKM2 enzymes were
treated with thrombin in order to cleave the GST-tag from the recombinant
protein and result in PKM2 elution from the column matrix. Bacterial lysates or
elutions following thrombin cleavage were subjected to SDS-PAGE and
Coomassie staining.
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B.

Figure 12. Purification of His-tagged PKM2 proteins. (A) Initial
purification of His-WT PKM2 from IPTG-induced BL21 cells with Ni-NTA
sepharose resulted in the presence of higher molecular weight proteins upon
elution with imidazole. (B) Optimization of expression/extraction protocol led to
purification WT, MT1, MT2, and MT4 His-PKM2 from Ni-NTA sepharose.
Aliquots from lysates, washes, or imidazole elutions were subjected to SDSPAGE and Coomassie staining. Expected molecular weight of His-PKM2 is
approximately 60kDa.
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unable to discern the presence of any His-PKM2 protein. I further developed the
purification protocol for the His-PKM2 proteins by changing the extraction/binding
buffers and the addition of sonication to the bacterial lysates. After optimization, I
was able to recover His-PKM2 WT, MT1, MT2, MT3, and MT4 to greater than 95%
purity (Figure 12B, only WT, MT1, MT2, and MT4 are shown). I have noticed that
His-PKM2-MT4 consistently resulted in lower yield compared to the other samples,
but this may be due to lower overall extracted proteins in bacteria (Figure 12B).
Kinetic Analysis of His-PKM2 Enzymes
To determine that the protein concentration to be used in the kinetic analysis
would be within a linear relationship of initial velocity and enzyme concentration, I
first measured initial velocities (mOD absorbance / min) within a range of HisPKM2 concentrations, from 1.0 to 4.0nM of the enzyme. Unlike the GST-PKM2
enzymes, I found that His-PKM2 proteins showed activity within the LDH coupled
assay (Figure 13 A-C; data shown for PKM2 MT1, MT2, and MT4). From these
studies, I selected 2.5 nM as an optimal concentration for kinetic characterization
of these enzymes (Figure 13A-C). Western blot analysis was also performed
comparing His-PKM2 proteins across separate preparations [Batch 1 (B1) or Batch
2 (B3)] to ensure that they were similar across all samples (Figure 14 A-B).
I next proceeded to measure His-PKM2 activity, using 2.5nM of each
enzyme, across multiple concentrations of PEP, ranging from 0.025mM to 4mM.
Using the NADH extinction coefficietny, the initial linear slope of NADH
consumption (mOD / min) can be converted to an initial velocity kinetic rate for
PKM2 of nmol / min of PEP at a specified PEP concentration. The average initial
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B.
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Figure 13. Kinetic analysis to determine optimal PKM2
concentration. Rates of NADH consumption was measured under increasing
concentrations of His-PKM2. Depicted are the reads from MT1 (A) MT2 (B) and
MT4 (C). Points were plotted based on mOD/min and were fit to linear
regression analysis.
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C o n c e n tra tio n o f P E P (m M )

His-PKM2
Vmax
(nmol/min)
Km
(mM)

Wild-Type
0.7733
(0.04974)
0.2816
(0.05274)

Mutant 1
0.7634
(0.1001)
0.7517
(0.264)

Mutant 2
1.272
(0.02924)
0.3915
(0.02123)

Mutant 3
N/A
N/A

Mutant 4
0.4893
(0.06719)
0.705
(0.2489)

Figure 14. Kinetic analysis of WT or MT His-PKM2 enzymes. His-tagged
WT, MT1, MT2, MT3, and MT4 PKM2 were purified using Ni-NTA as described in the
materials and methods (A & B) Western blots of His-PKM2 proteins from Batch 1 and
2 were performed to aid in concentration adjustments for the kinetic assays. (C)
Average initial velocities of the His-PKM2 proteins (2.5nM) in the presence of
increasing concentrations of PEP. Data is represented as nmol / min and fitted to a
non-linear regression analysis. Results are an average of two experiments using
protein preparations from either batch 1 or batch 2 that incorporate two technical
replicates. Average kinetic parameters (Vmax and Km) for each enzyme is detailed
within the table with the standard deviations indicated within the parentheses.
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Figure 15. Vmax differences between His-PKM2.
Comparison of calculated Vmax values across wild-type or
different mutant His-PKM2 enzymes.
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Figure 16. Km differences between His-PKM2. Calculated
Km values of His-PKM2 WT, MT1, MT2, and MT4.
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velocities (nmol / min) were plotted versus PEP concentration for the WT and MT
His-PKM2 proteins from both preparations (Figure 14C; plots for each individual
enzyme are shown in Appendix Figures 29-36). Non-linear regression analysis
was used to determine both the maximum velocity (Vmax) and Michaelis-Menten
constant (Km) for each enzyme. The calculated average Vmax for WT, MT1, MT2,
and MT4 His-PKM2 were 0.77, 0.76, 1.3, and 0.49 (nmol / min), respectively. The
Km values for WT, MT1, MT2, and MT4 His-PKM2 were determined to be 0.28,
0.75, 0.39, 0.70 mM (Figure 14C), respectively. No activity was detected for HisPKM2 MT3 across any concentrations of PEP. The specific activity of human WT
PKM2 has been previously reported as 116 μmol/min/mg protein [47]. His-PKM2
WT used in these studies exhibited a specific activity of 55 μmol/min/mg.
Comparison of activity of His-PKM2 WT to mutant enzymes indicate that mutations
within MT1 did not alter Vmax, yet amino acid changes within MT2 led to an increase
in Vmax (Figure 15). In addition, mutation of a single amino acid in His-PKM2 MT4
resulted in decreased activity. While not significant, mutations in either His-PKM2
MT1 or MT4 appeared to increase the Km for PEP compared to WT (0.28 vs.
0.75mM or 0.70mM, respectively) (Figure 14B-C&16). To assess the effect of
these mutations on the overall catalytic efficiency of PKM2, we calculated the
Kcat/Km of 1.83x105, 6.7x104, 2.16x105, and 4.6x104 M-1sec-1 for the WT, MT1,
MT2, and MT4 enzymes, respectively. Mutations within MT1 and MT4 led to a
decrease in enzyme efficiency of 60 and 75% compared to WT PKM2, while
mutations in MT2 caused a 20% increase in Kcat/Km. Surprisingly, combining amino
acid changes in MT2 and MT4 within MT3, completely abolished any detectable

44

PKM2 function within the LDH-coupled assay. Taken together, these data suggest
that these amino acid changes can either increase (MT2) or decrease (MT1 and
MT4) the kinetic activity of PKM2, particularly its catalytic efficiency, while the
combination of mutations within MT2 and MT4 abolish all activity (MT3).
Examination of Oligomer States of His-PKM2 Proteins
PKM2 can exist as a monomer, dimer, and tetramer and these varying
oligomer states can influence enzymatic activity. As I observed differences in
enzymatic activity in mutant His-PKM2 proteins, particularly complete loss in MT3,
I next wanted to determine if the mutations changed the oligomerization of PKM2.
For this, 50ng aliquots of His-PKM2 enzymes (study performed with proteins
purified from batch 2) were incubated with disuccinimidyl suberate (DSS), which is
a non-cleavable, cell permeable protein cross-linker. Enzymes were then
subjected to SDS-PAGE and immunoblot analysis. Under these conditions, DSS
cross-linking resulted in the formation of dimer and tetramer states for the PKM2
enzymes (Figure 17). As a positive control, FBP was added 30 minutes before
DSS crosslinking, which resulted in greater tetramer formation of WT His-PKM2
(Figure 17, compare lanes 1 & 8). Cross-linking of His-PKM2 MT3 revealed the
presence of large molecular weight aggregates (~300kDa) beyond dimer and
tetramer forms of PKM2. The presence of these aggregates may explain the lack
of activity of MT3 within the kinetics assay, as aggregation may have limited the
concentration of potentially active protein within the assay.
Influence of PSAT1 on His-PKM2 Enzymes
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Figure 17. Cross-linking analysis to assess oligomerization of HisPKM2 proteins. 50ng aliquots of His-PKM2 WT and MT proteins (Batch 2)
were cross-linked with DSS (left: 10μM; right: 20μM) as described in the
materials and methods. Samples were then subjected to SDS-PAGE and
immunblotted for His. Additional preparations of WT PKM2 without DSS or in
the presence of DSS and 500μM FBP were performed to define monomer
PKM2 and assess FBP on tetramer formation, respectively. Shown are
representative Western blots of two separate experiments.
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After defining the kinetic activity of His-PKM2 WT, MT1, MT2, MT3, and
MT4, I next assessed the effect of PSAT1 on the activity of each enzyme. Using
the kinetic protocol described above, 400nM PSAT1 was incubated with the HisPKM2 proteins before initiation of the LDH-coupled kinetics assay. Unlike what
was previously observed in the preliminary studies using untagged PKM2-Sigma,
I found that addition of PSAT1 was unable to increase the activity of any of the HisPKM2 enzymes (Figure 18-22; plots for each enzyme from both batches is shown
in Figures 29-36 in the Appendix). In addition, there was no significant change in
the Km for PEP of any of the His-PKM2 proteins in the presence of PSAT1 (Figure
25).

To ensure that the His-PKM2 enzymes were capable of responding to

external stimulus, I added 500μM of FBP before initiating the kinetic assays. For
all of the active His-PKM2, FBP was found to considerably decrease the Km for
PEP (Figures 18-22). This shift in Km is not unexpected as this has previously been
reported for PKM2 and the crosslinking experiments showed an increase in the
tetrameric state of, at least, His-PKM2 WT, in the presence of FBP (Figure 17).
These results indicate that, unlike the preliminary data utilizing untagged PKM2Sigma within the ADP-glo assay, PSAT1 was unable to increase His-PKM2
activity, even though these His-tagged enzymes still possessed the ability to be
activated by FBP.
Direct Comparison of His-PKM2 and untagged PKM2-Sigma
To determine whether this discrepancy is due to the use of different assays, I
directly compared the effect of PSAT1 addition on PKM2-Sigma within both the
LDH-coupled assay as well as His-PKM2 WT within the ADP-glo. I first performed
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Western blot analysis to demonstrate that the protein levels of both His-PKM2 and
PKM2-Sigma were similar, and that PKM2-Sigma does not contain a His-tag
(Figure 23A). Analysis of PKM2-Sigma within the LDH-coupled assay determined
a Vmax of 0.77 nmol / min, similar to that observed with His-PKM2. Unlike HisPKM2, upon incubation with PSAT1, PKM2-Sigma exhibited an increase in Vmax
(0.95 nmol / min), a decrease in the Km to 0.38 mM, and an 2.2 fold increase in
catalytic efficiency (Figure 23B). To verify this result and determine whether HisPKM2 may be stimulated in other assays, I repeated the ADP-glo protocol with
both His-PKM2 WT and PKM2-Sigma. Similar to that observed with the LDHcoupled assay, PSAT1 failed to enhance the activity of His-PKM2 compared to
PKM2-Sigma (Figure 26). Together these data suggest that while His-PKM2
proteins maintain enzymatic activity that can be stimulated with known allosteric
activators, something inherent in these recombinant proteins is precluding
activation by PSAT1. Direct comparison with PKM2-Sigma suggests that the
presence of the His-tag on the His-PKM2 proteins may disrupt the association with
PSAT1 that is observed with un-tagged PKM2-Sigma.
ASSESSMENTS FOR INTERACTION BETWEEN WILD-TYPE AND MUTANT
HIS-PKM2 ENZYMES AND PSAT1
PSAT1 associates non-specifically to Ni-NTA beads
To determine whether the His-PKM2 proteins were able to associate with PSAT1,
I performed a pull-down assay using His-PKM2 WT and Ni-NTA sepharose beads.
As a negative control, a separate sample was added that contained PSAT1 and
Ni-NTA beads without His-PKM2. After pulldown with Ni-NTA, recovered proteins
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Figure 18. Effect of PSAT1 and FBP on WT His-PKM2 activity.
Enzymatic activity of WT His-PKM2 (2.5nM) was measured by an enzymecoupled assay with increasing concentrations of PEP in the presence or
absence of PSAT1 or FBP. Data is represented as nmol / min and fitted to a
non-linear regression analysis. Results are an average of two experiments
using protein preparations from either batch 1 or batch 2 that incorporate two
technical replicates. Table depicts average kinetic parameters (Vmax and Km) for
each condition with standard deviation indicated within the parentheses.
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Figure 19. Effect of PSAT1 and FBP on MT1 His-PKM2 activity.
Enzymatic activity of MT1 His-PKM2 (2.5nM) was measured by an enzymecoupled assay with increasing concentrations of PEP in the presence or
absence of PSAT1 or FBP. Data is represented as nmol / min and fitted to a
non-linear regression analysis. Results are an average of two experiments
using protein preparations from either batch 1 or batch 2 that incorporate two
technical replicates. Table depicts average kinetic parameters (Vmax and Km) for
each condition with standard deviation indicated within the parentheses.

50

His-PKM2 MT2
2.0

PKM2
PKM2 + 400nM PSAT1

nmol/min

1.5

PKM2 + 500uM FBP
1.0
0.5
0.0
0

1

2

3

4

5

Concentration of PEP (mM)

His-PKM2 MT2
Vmax
Km

+
1.272
(0.02924)
0.3915
(0.02123)

+
+400nM PSAT1
1.412
(0.01489)
0.3455
(0.008683)

+
+500uM FBP
1.281
(0.04464)
0.1237
(0.01375)

Figure 20. Effect of PSAT1 and FBP on MT2 His-PKM2 activity.
Enzymatic activity of MT2 His-PKM2 (2.5nM) was measured by an enzymecoupled assay with increasing concentrations of PEP in the presence or
absence of PSAT1 or FBP. Data is represented as nmol / min and fitted to a
non-linear regression analysis. Results are an average of two experiments
using protein preparations from either batch 1 or batch 2 that incorporate two
technical replicates. Table depicts average kinetic parameters (Vmax and Km) for
each condition with standard deviation indicated within the parentheses.

51

H is - P K M 2 M T 3
0 .0 6

PKM 2

n m o l/m in

PKM 2 + 400nM PSAT1
0 .0 4

PKM 2 + 500uM FBP

0 .0 2

0 .0 0
0

1

2

3

4

5

C o n c e n tr a tio n o f P E P (m M )

Figure 21. Effect of PSAT1 and FBP on MT3 His-PKM2 activity.
Enzymatic activity of MT3 His-PKM2 (2.5nM) was measured by an enzymecoupled assay with increasing concentrations of PEP in the presence or
absence of PSAT1 or FBP. Data is represented as nmol / min and fitted to a
non-linear regression analysis. Results are an average of two separate
experiments incorporating two technical replicates.

52

His-PKM2 MT4
1.5

PKM2

nmol/min

PKM2 + 400nM PSAT1
1.0

PKM2 + 500uM FBP

0.5

0.0
0

1

2

3

4

5

Concentration of PEP (mM)

His-PKM2 MT4
Vmax
Km

+
0.4893
(0.06719)
0.705
(0.2489)

+
+400nM PSAT1
0.6056
(0.06349)
0.822
(0.2173)

+
+500uM FBP
0.9758
(0.06354)
0.1158
(0.002574)

Figure 22. Effect of PSAT1 and FBP on MT4 His-PKM2 activity.
Enzymatic activity of MT4 PKM2 (2.5nM) was measured by an enzyme- coupled
assay with increasing concentrations of PEP in the presence or absence of
PSAT1 or FBP. Data is represented as nmol / min and fitted to a non-linear
regression analysis. Results are an average of two experiments using protein
preparations from either batch 1 or batch 2 that incorporate two technical
replicates. Table depicts average kinetic parameters (Vmax and Km) for each
condition with standard deviation indicated within the parentheses.
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Figure 23. Kinetic analysis of PKM2-Sigma activity in the presence
of PSAT1. (A) Representative Western blot comparing purified His-PKM2 WT
with PKM2-Sigma. 50ng of enzyme was separated by SDS-PAGE and
immunobloted using His or PKM2 specific antibodies. (B) Enzymatic activity of
PKM2-Sigma (2.5nM) was measured by enzyme-coupled assay with increasing
concentrations of PEP in the presence or absence of PSAT1. Data is
represented as nmol / min and fitted to a non-linear regression analysis. Results
are an average of two separate experiments incorporating two technical
replicates. Table depicts average kinetic parameters (Vmax and Km) for each
condition with standard deviation indicated within the parentheses.
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Figure 24. Vmax differences between samples Graph representing the
differences in Vmax among the recPKM2 in the presence of either PSAT1 or FBP
(n = 2).
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Figure 25. Km differences between samples Graph representing the
differences in Km among the recPKM2 in the presence of either PSAT1 or FBP
(n = 2).
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Figure 26. Alternative analysis of recPSAT1 activation of inhouse and commercial WT PKM2. Both recPKM2 enzymes were
incubated with increasing concentrations of PSAT1 and pyruvate kinase
activity was measured by AD-Glo as described in the materials and
methods. Data at each PSAT1 concentration is represented as average
% RLU change from activity observed without PSAT1. Shown is mean ±
SD from two separate experiments incorporating two technical
replicates.
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were separated by SDS-PAGE and PSAT1 interaction was assessed by Western
blot. First, I was able to successfully pull-down His-PKM2 WT from the protein
mixture (Figure 27A, Lane 2-4; input of His-PKM2 for reference in Lane 5).
However, while there was a significant level of PSAT1 observed in the His-PKM2
pull-down sample (Figure 27A, Lanes 2-3; input of PSAT1 for reference in Lane
1), I also found that PSAT1 appeared to be non-specifically binding to the Ni-NTA
beads in the absence of His-PKM2 (Figure 27A, lane 6). To ensure that PSAT1
did not contain an unexpected His-tag that was mediating its binding to the Ni
beads, I incubated PSAT1 with beads alone and performed Western blot using
antibodies specific for His- tag or PSAT1. As illustrated in Figure 27B, PSAT1
does, in fact, interact with Ni-NTA bead matrix and does so without a His-tag, as
the anti-His Western blot failed to show any PSAT1 in samples containing PSAT1
and Ni-NTA. Together, these data suggest that use of Ni-NTA pulldown protocol is
not compatible to assess PKM2:PSAT1 interaction due to PSAT1’s non-specific
binding to the nickel beads.
Co-immunoprecipitation of PSAT1 and PKM2
Due to the complications that were seen using PSAT1 and Ni-NTA, I decided to
perform co-immunoprecipitation analysis to examine the interaction with PSAT1
and WT or MT His-PKM2 proteins. This approach was used to demonstrate the
selective association of PSAT1 with un-tagged PKM2-Sigma within the preliminary
studies.

Immunoblot analysis for PSAT1 demonstrated that the anti-PSAT1

antibody was able to significantly precipitate PSAT1 from the protein mixture
(Figure 28, compare lanes 1-5 to lanes 6-10 for IgG control). However, Western
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blot for His-tagged PKM2 failed to show any enrichment of the His-PKM2 proteins
with precipitation of PSAT1 (Figure 28). These indicate that unlike PKM2-Sigma
that was found to directly interact with PSAT1, His-PKM2 enzymes fail to associate
with PSAT1. While it is unclear as to why these enzymes fail to interact with PSAT1
(certain hypothesis will be discussed below), these data may explain the lack of
activation of these proteins in the presence of PSAT1.
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Figure 27. Analysis of PSAT1:PKM2 interaction using His-PKM2
pulldown with Ni-NTA. (A) 50ng of His-PKM2 WT was incubated with 500ng
of PSAT1. Ni-NTA beads were used to pulldown complex and elutions were
analyzed by immunoblot analysis. Shown is representative Western blot using
specific His (PKM2) or PSAT1 antibodies. Input lanes have been labeled in
addition to lane numbers. (B) PSAT1 was incubated with Ni-NTA alone and
elutions were analyzed by Western blot using anti-His or anti-PSAT1 antibodies.
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Figure 28. Co-IP of recombinant PSAT1 and PKM2. Co-IP analysis was
done on mixture of PSAT1 (50ng) and 500ng of His-PKM2 proteins. Co-IP was
performed using anti-PSAT1 or normal rabbit IgG (negative control). Shown is a
representative Western blot of immunocomplexes using anti-His (PKM2) or antiPSAT1 antibodies.
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CHAPTER FOUR: DISCUSSION
The goal of this project was to define the consequence of PSAT1
association on the enzymatic activity of PKM2. This was based on preliminary
studies that performed mass spectrophotometry on PSAT1 to identify novel
binding partners and found PKM2 among the list of possible interacting proteins.
Through an ADP-Glo kinase assay it was shown that addition of PSAT1 led to
increased PKM2-Sigma activity. Further, site-directed mutations identified specific
amino acids that suggested contribution to the interaction between both proteins.
These findings led to my hypothesis that the direct association of PSAT1 was
necessary for PKM2 activation and that loss of interaction between PSAT1 and
PKM2 due to these PKM2 mutations would prevent PSAT1 activation of PKM2. I
aimed to test this hypothesis by defining the activity of WT and MT forms of PKM2,
determining the effect of PSAT1 on their activity, and assessing their interaction
with PSAT1. To initiate these experiments, I first needed to express and purify
recombinant proteins by incorporation of a fusion tag.
Tags encoded by expression vectors differ in their size and the matrix that
is used to purify the fusion proteins. Included among these are histidine and GST
tags that can be purified using nickel or glutathione-linked sepharose, respectively.
Experimental end-point, as well as effects on the solubility of the fusion protein,
are factors to be considered when selecting a specific tag.

PKM2 can be

challenging to express recombinantly, but others have reported that the inclusion
of a GST tag assists in proper protein folding [73]. Thus, I began by sub-cloning
the cDNAs encoding WT, MT1, MT2, and MT3 PKM2 into a pGEX4T-1 vector.
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After cloning, GST-PKM2 was purified under non-denaturing ionic conditions, as
others have demonstrated that this method increases protein yield [72]. Initial
attempts utilizing this Sarkosyl:Triton X100 procedure resulted in no GST-PKM2
purification (Figure 9), leading me to optimize my expression protocols (different
lysing methods) to obtain significant yield (Figure 10).
One potential issue with using fusion-tagged proteins is the effect of the tag
on the activity of the enzyme. Using an enzyme-coupled assay to measure PKM2
activity, I found that the GST-PKM2 WT and MT proteins displayed no pyruvate
kinase activity (Figure 10). As I had performed the preparation protocol under nondenaturing conditions and Coomassie staining revealed little to no contaminating
proteins, I concluded that the large GST tag was inhibiting enzymatic activity. The
lack of activity could be potentially due to either changing the overall structure of
PKM2, preventing oligomerization, or inhibiting substrate binding. In order to
remove the tag, I decided to utilize the thrombin cleavage site that is encoded
between the GST tag and PKM2. However, no PKM2 protein was recovered
following thrombin cleavage; making it unfeasible to assess enzyme activity. Due
to these experimental issues, I decided use a separate expression system to purify
the WT and MT PKM2 proteins.
Purification using a His-fusion expression system has been shown to result
in active pyruvate kinase [55]. After optimizing the purification protocol (Figure 13),
I was able to produce active His-PKM2, as assessed in the LDH-coupled assay.
The calculated specific activity of my purified His-PKM2 WT (55 μmol / min / mg),
which is half of what has been previously published by others (116 μmol / min /
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mg) [47]. As point mutations have been previously reported to alter PKM2 activity
[55], I proceeded to define the kinetics of all four mutant His-PKM2 forms.
In my studies, the introduction of the separate mutations resulted in different
kinetics for His-PKM2. While mutations in MT1 did not appear to alter activity
compared to WT; MT2 His-PKM2 demonstrated an increase in Vmax. Yet, these
amino acid changes within MT2 did not significantly alter the Km for PEP. This
suggests that these mutations may modify the protein structure in such a way as
to distort the active site, resulting in lower activation energy and increased pyruvate
formation. Conversely, MT4 exhibited a slight decrease in Vmax, indicating that
these mutations negatively affect enzyme activity. However, amino acid changes
in MT3 His-PKM2 entirely abolished pyruvate kinase activity.
The complete lack of activity is surprising in that MT3 is a combination of
mutations found in MT2 and MT4 His-PKM2. As other site-specific mutations have
previously been shown to affect dimer/tetramer formation of PKM2, cross-linking
studies were done to assess effects on the oligomerization of His-PKM2. I found
that MT3 forms high molecular weight aggregates under native conditions
compared to WT and other MT His-PKM2 proteins. From this, it still needs to be
determined whether these mutations abolish activity due to inducing His-PKM2
misfolding and aggregation. The cross-linking experiments also showed that there
were no adverse effects on dimer/tetramer formation between WT, MT1, MT2, or
MT4 suggesting that the differences observed in activity may not be a result of
changes in oligomer formation.
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Next, I determined the effect of PSAT1 on the activity of all forms of HisPKM2. While the preliminary studies demonstrate that PSAT1 stimulates PKM2Sigma, PSAT1 failed to activate any of the His-PKM2 proteins. To determine
whether these enzymes respond to other activators, I added FBP and observed
either significant increases in enzyme activity, lowering of Km for PEP, or both as
has been previously described for FBP. This is supported, at least with His-PKM2
WT, that addition of FBP leads to greater tetramer formation, which is well
established to increase PKM2 activity. Lastly, to determine whether it was a
difference in assays that were leading to the discrepancy in the ability of PSAT1 to
activate His-PKM2, I repeated both the LDH-coupled assay and the ADP-Glo using
both PKM2-Sigma and His-PKM2 WT.

I observed that PSAT1 was able to

stimulate PKM2-Sigma in both assays, while His-PKM2 WT failed to show any
increase. Together, these data suggest that the His-tag on the PKM2 enzymes
was inhibiting the transactivation potential of PSAT1, potentially through blocking
the association between PSAT1 and the His-PKM2 proteins.
Since the preliminary data suggested that PSAT1’s interaction with PKM2Sigma allows for activation, I performed association studies to determine the amino
acid requirement for PSAT1:PKM2 interaction. However, I was unable to observe
interaction with any of the active His-PKM2 enzymes. Both Ni-NTA pulldown and
co-immunoprecipitation studies demonstrated a lack of specific interaction
between PSAT1 and His-PKM2. Attempting to pull-down PSAT1 using HisPKM2:Ni-NTA chromatography proved to be ineffective, as PSAT1 was found to
bind non-specifically to the nickel beads. Also, co-immunoprecipitation analysis
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using a PSAT1 antibody, similar to that used in the preliminary studies with PKM2Sigma, failed to enrich levels of His-PKM2 above that of the IgG negative control.
Together, my interaction experiments suggest that His-PKM2 proteins are unable
to associate with PSAT1. While not conclusive, this could explain the lack of
activation of His-PKM2 upon addition of PSAT1.
As demonstrated by Western blot, PKM2-Sigma does not contain a His-tag.
While unexpected, cumulatively, my data indicate that the His-tag within the HisPKM2 enzymes is affecting the interaction with PSAT1. Yet, another possible
reason relates to potential differences in the purification scheme used to produce
both the PKM2-Sigma and His-PKM2 proteins. Buffers used to lyse, wash, elute,
and even dialyze PKM2 could lead to differences in the ability to interact with
PSAT1. A shift in pH between two separate buffers could be a determining factor
as to whether proteins associate. Lastly, PSAT1 requires a co-factor, PLP, for its
enzymatic activity and in theory optimal tertiary structure. I did not add this cofactor to either the His-PKM2 enzymatic or associating assays. However, I do not
believe that this contributed to the lack of effect, as the preliminary data using
PKM2-Sigma also did not add exogenous PLP.
Future studies related to this project should be focused on identifying other
purification schemes to purify the PKM2 enzymes. As thrombin cleavage was
inefficient in obtaining PKM2 enzymes, cDNA can be sub-cloned into other GSTfusion vectors that contain cleavage sites for other enzymes, such as PreScission
Protease. As informative as these results are regarding the kinetic characteristics
of WT and MT His-PKM2 proteins, the question persists of what region/amino
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acids of PKM2 is required for binding to PSAT1. Importantly, while the preliminary
data suggest that amino acids that make up MT3 aid in disassociating PSAT1, they
may lead to overall structural changes in PKM2 and may not be directly involved
in the interaction with PSAT1. This could also be addressed through computational
programs, such as the Rosetta Online Server that Includes Everyone (ROSIE).
ROSIE uses a Monte Carlo based algorithm to predict the likelihood of two
proteins interacting with one another using its structure-prediction based program
[71]. Although ROSIE is capable of prediction protein: protein interaction, separate
tools must be used to prepare the proteins of interest structure for ROSIE docking.
Protein structures, attained in the form of protein data banks (PDB) files, are
loaded into separate computer software for molecular visualization such as PyMol
or Chimera. Within the software, users are capable of manipulating the protein
structure through the removal, addition, or replacement of amino acids. When
investigating possible protein: protein interaction, it is crucial that the regions that
are believed to have a role in the interaction be positioned nearby one another.
The purpose of this positioning becomes apparent when simulating protein: protein
interaction through ROSIE, which performs local docking on the given starting
conformation of the proteins involved. The resulting output from ROSIE is a list of
possible protein conformations with the 10 lowest-energy needed structures being
prominently displayed.
As these two proteins play essential roles in tumor metabolism, ultimately
characterizing their functional association in the context of changing glucose
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and/or serine metabolism will provide a more comprehensive understanding of
cellular changes during tumorigenesis.
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APPENDIX
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(0.01189)
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(0.0081)
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0.8501
(0.01489)
0.1521
(0.008032)

Figure 29. Effect of PSAT1 and FBP on WT His-PKM2 (Batch1)
activity. Enzymatic activity of WT PKM2 (2.5nM) from Batch 1 was measured
by an enzyme- coupled assay with increasing concentrations of PEP in the
presence or absence of PSAT1 or FBP. Data is represented as nmol / min and
fitted to a non-linear regression model. Results are an average of two technical
replicates. Table depicts average kinetic parameters (Vmax and Km) for each
condition. SD is indicated within the parentheses.
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Figure 30. Effect of PSAT1 and FBP on MT1 His-PKM2 (Batch1)
activity. Enzymatic activity of MT1 PKM2 (2.5nM) from Batch 1 was measured
by an enzyme-coupled assay with increasing concentrations of PEP in the
presence or absence of PSAT1 or FBP. Data is represented as nmol / min and
fitted to a non-linear regression model. Results are an average of two technical
replicates. Table depicts average kinetic parameters (Vmax and Km) for each
condition. SD is indicated within the parentheses.
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Figure 31. Effect of PSAT1 and FBP on MT2 His-PKM2 (Batch1)
activity. Enzymatic activity of MT2 PKM2 (2.5nM) from Batch 1 was measured
by an enzyme-coupled assay with increasing concentrations of PEP in the
presence or absence of PSAT1 or FBP. Data is represented as nmol / min and
fitted to a non-linear regression model. Results are an average of two technical
replicates. Table depicts average kinetic parameters (Vmax and Km) for each
condition. SD is indicated within the parentheses.
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Figure 32. Effect of PSAT1 and FBP on MT4 His-PKM2 (Batch 1)
activity. Enzymatic activity of MT4 PKM2 (2.5nM) from Batch 1 was measured
by an enzyme-coupled assay with increasing concentrations of PEP in the
presence or absence of recPSAT1 or FBP. Data is represented as nmol / min
and fitted to a non-linear regression model. Results are an average of two
technical replicates. Table depicts average kinetic parameters (Vmax and Km) for
each condition. SD is indicated within the parentheses

77

B .2 - H is - P K M 2 W T
1 .5

PKM2

n m o l/m in

PKM 2 + 400nM PSAT1
1 .0

PKM 2 + 500uM FBP

0 .5

0 .0
0

1

2

3

4

5

C o n c e n t r a t io n o f P E P ( m M )

B2
Vmax
Km

His-PKM2 WT
0.8934
(0.05763)
0.6041
(0.1068)

His-PKM2 WT
+400nM PSAT1
0.867
(0.2191)
1.076
(0.917)

His-PKM2 WT
+500uM FBP
1.087
(0.02343)
0.126
(0.009584)

Figure 33. Effect of PSAT1 and FBP on WT His-PKM2 (Batch 2)
activity. Enzymatic activity of MT4 PKM2 (2.5nM) from Batch 1 was measured
by an enzyme-coupled assay with increasing concentrations of PEP in the
presence or absence of recPSAT1 or FBP. Data is represented as nmol / min
and fitted to a non-linear regression model. Results are an average of two
technical replicates. Table depicts average kinetic parameters (Vmax and Km) for
each condition. SD is indicated within the parentheses
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Figure 34. Effect of PSAT1 and FBP on MT1 His-PKM2 (Batch 2)
activity. Enzymatic activity of MT4 PKM2 (2.5nM) from Batch 1 was measured
by an enzyme-coupled assay with increasing concentrations of PEP in the
presence or absence of recPSAT1 or FBP. Data is represented as nmol / min
and fitted to a non-linear regression model. Results are an average of two
technical replicates. Table depicts average kinetic parameters (Vmax and Km) for
each condition. SD is indicated within the parentheses
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Figure 35. Effect of PSAT1 and FBP on MT2 His-PKM2 (Batch 2)
activity. Enzymatic activity of MT4 PKM2 (2.5nM) from Batch 1 was measured
by an enzyme-coupled assay with increasing concentrations of PEP in the
presence or absence of PSAT1 or FBP. Data is represented as nmol / min and
fitted to a non-linear regression model. Results are an average of two technical
replicates. Table depicts average kinetic parameters (Vmax and Km) for each
condition. SD is indicated within the parentheses
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Figure 36. Effect of PSAT1 and FBP on MT4 His-PKM2 (Batch 2)
activity. Enzymatic activity of MT4 PKM2 (2.5nM) from Batch 1 was measured
by an enzyme-coupled assay with increasing concentrations of PEP in the
presence or absence of recPSAT1 or FBP. Data is represented as nmol / min
and fitted to a non-linear regression model. Results are an average of two
technical replicates. Table depicts average kinetic parameters (Vmax and Km) for
each condition. SD is indicated within the parentheses
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Abb.
PKM2
PSAT1
recPKM2
ATP
HK
G6P
PGI
F6P
PFK1
FBP
G3P
GAPDH
NAD
ADP
PEP
PK
TCA
FAD
LDH
FDG
PET
CT
HIF1⍺
PPP
NADP
ROS
PHP
PHGDH
PLP
⍺KG
P-ser
PSPH
THF
SAM
hnRNP
SRSF 3

Name
Pyruvate Kinase M2 isoform
PhosphoSerine AminoTransferase 1
Recombinant PKM2 protein
Adenosine TriPhosphate
Hexokinase
Glucose 6-Phosphate
PhosphoGlucose Isomerase
Fructose 6-Phophate
PhosphoFructoKinase-1
Fructose 1,6-BisPhosphate
Glyceraldehyde 3-Phosphate
GlycerAldehyde 3-Phosphate
DeHydrogenase
Nicotinamide Adenine Dinucleotide
Adenosine DiPhosphate
PhosphoEnolPyruvate
Pyruvate Kinase
TriCarboxylic Acid
Flavin Adenine Dinucleotide
Lactate DeHydrogenase
FluroDeoxyGlucose
Positron Emission Tomography
Computed Tomography
Hypoxia Inducing Factor 1 ⍺
Pentose Phosphate Pathway
Nicotinamide Adenine Dinucleotide
Phosphate
Reactive Oxygen Species
3-PhosphoHydroxyPyruvate
PHosphoGlycerate DeHydrogenase
PyridoxaL 5'-Phosphate
⍺-KetoGlutarate
PhosphoSERine
PhosphoSerine PHosphatase
TetraHydroFolate
S-Adenosyl Methionine
HeterogeNous RiboNucleoProteins
Serine-aRgenine Splice Factor 3
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H3T11
mTHF
MT1
MT2
MT3
MT4
WT
B.1
B.2

Tyrosine 11 on Histone H3
methyl TetraHydroFolate
Mutant 1
Mutant 2
Mutant 3
Mutant 4
Wild-Type
Batch 1
Batch 2

Table 1. Abbreviations
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Assessment of interaction of His-PKM2 with Glutathione Beads
The PSAT1:PKM2 association was originally identified through a GSTPSAT1 pulldown. To determine the feasibility of this strategy to investigate HisPKM2 association, I first wanted to test if His-PKM2 non-specifically bound to
glutathione beads. For this, 0.1% of BSA was added to Glutathione beads and
incubated overnight at 4oC. 500ng of His-PKM2 was added to the solution and
incubated at 4oC for an additional 45 minutes. Beads were centrifuged, and
supernatant was discarded.

Beads were washed 3 times using 1x PBS,

centrifuged, and supernatant was discarded. 25L of 1x Laemmli Buffer was
added to the beads and heated to 95oC for 5 minutes.

Beads were then

centrifuged, and supernatant was loaded onto 10% SDS-PAGE gel. Binding of HisPKM2 to glutathione beads was assessed by immunoblotting using anti-His
antibody. As depicted in Figure 37, no His-PKM2 was seen bound to GST beads.
These data suggest that binding of His-PKM2 protein to GST-PSAT1 may be
evaluated with this approach.
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His-PKM2

Figure 37. Analysis of His-PKM2 association with glutathione beads.
His-tagged PKM2 proteins were incubated with glutathione beads alone. Elutions
were ran on SDS-PAGE and shown is an individual Western blot assessing
presence of PKM2 using an anti-His antibody. Aliquot of recPKM2 WT was used
as positive control for immunoblot.

85

CURRICULUM VITAE

Alexis Vega
744 E Madison St. 744A
Louisville, KY 40202
Telephone: (239)895-6213
aavega01@exchange.louisville.edu

A. Education
University of Louisville
Louisville, KY
Master’s in Science, Molecular Biology and Molecular Genetics
Florida Gulf Coast University
Fort Myers, FL
Bachelor’s in Science, Biotechnology
Miami-Dade Community College
Miami, FL
Associate’s in Arts, Biotechnology
B. Academic Appointments
James Brown Cancer Center
Louisville, KY
Lab Technician I
PI: Dr. Brian F. Clem
Investigating the interaction between recombinant PKM2 and
PSAT1
C. Abstracts and Presentations
Graduate Student Regional Research Conference
Louisville, KY
PI: Dr. Brian Clem
Functional consequence of association of PKM2 and PSAT1 on
their inherent enzymatic activity
Research! Louisville
Louisville, KY
PI: Dr. Brian Clem
Functional consequence of association of PKM2 and PSAT1 on
their inherent enzymatic activity
BMG Retreat
Louisville, KY
PI: Dr. Brian Clem
86

08/2016
Present
08/2011
04/2014
08/2009
04/2011

01/2017
05/2018

03/2018

09/2017

08/2017

Functional consequence of association of PKM2 and PSAT1 on
their inherent enzymatic activity
Florida Gulf Coast University Research Day
Fort Myers, FL
PI: Dr. Jan DeJarnette
Determining Whether Certain Strains of Methicillin-Resistant
Staphylococcus aureus have Sexual Preferences
A. Research Funding
Graduate School Committee Research Award
University of Louisville, PI: Dr. Brian F. Clem
Role: Project Investigator (90%)
Funding amount: $500 (Indirect)

87

03/2014

2017

